Dana C. Matthews, MD
Cancer and Blood Disorders Center
On staff since March 1988
Children's Title: Director, Clinical Hematology; Chair, Blood Usage Committee
Academic Title: Professor
Research Center: Center for Clinical and Translational Research
"Every time I walk into a clinic room to meet a new patient, I enjoy getting to know the patient and the parents, perhaps hearing a new language and learning something about what their life is like. I try hard to understand what they know, what they do not know, how I can best explain the diagnosis, and how we can work together most effectively to make decisions about diagnosis and treatment. I am profoundly fortunate to work with colleagues who are smart, warm and witty people as well as great clinicians. They care about our patients and about their colleagues on our team. Working together is stimulating, fun and gratifying."
-
Dana C. Matthews, MD, is director of clinical hematology at Seattle Childrens Hospital and head of the Pediatric Hemophilia Program; she is associate professor at the University of Washington School of Medicine. Her research interests include risk-based optimization of the treatment of pediatric thrombosis, clinical outcomes in patients with hemophilia, and novel treatments for immune thrombocytopenic purpura (ITP).
Current and pending research includes involvement in an international project to characterize immune responses to factor VIII that result in inhibiting antibodies, a multicenter pediatric trial of a thrombopomimetic agent in ITP, and pilot pediatric studies of a novel oral anticoagulant. She is interested in improving the outcome for pediatric patients with thrombosis by developing a pediatric thrombosis registry and developing clinical trials for subgroups of patients with thrombosis. She is medical director of the Anticoagulation Service for Seattle Childrens Hospital, and chair of the Blood Usage Committee. National responsibilities include membership on the Certification and Continuing Education Committee and the Nominating Committee of the American Society of Pediatric Hematology/Oncology. She is a member of the Board of Directors of the American Board of Pediatrics, and is completing a term on the hematology-oncology subboard. She will be Medical Editor for that subboard beginning in 2011.
-
-
Dr. Dana Matthews is the best!! My daughter, Nicki, has been seeing Dana for 15 years now. Currently Nicki attends college in another state and she always looks forward to her visits with Dr. Matthews when she is back in town. She is dreading the day when Dr. Matthews tells her she can't see her anymore. Our family has always been extremely impressed with how caring and thoughtful Dana is with each member of our family. Every questions is answered thoughtfully. I receive responses to emailed questions faster than any other medical provider I have ever encountered. OUR ENTIRE FAMILY LOVES DR DANA MATTHEWS! We will greatly miss her when Nicki ages out of Seattle Children's.
-
Dr. Matthews is the most wonderful provider I've ever had. She was my pediatric hematologist and always did an exceptional job explaining my bleeding disorder to me, and working with me on how to manage my health. Dr. Matthews single handedly inspired me from a young age to be "just like her" and work in the healthcare industry as a helpful, caring & intelligent woman. Today I am an adult, working in healthcare, because of her overall positive impact on me. I'm extremely grateful for the care that Dr. Matthews provided me!
-
We are VERY impressed with this impressive doctor! She knows what she's doing and we are confident with her skills. Highly Recommended!!!
-
Dr. Matthews was warm, friendly and so helpful when she examined our failure-to-thrive baby. It's wonderful when a doctor who really knows their stuff also knows how to care for people. Thank you, Dr. Matthews.
-
Dr. Dana Matthews and her team are outstanding!!! We have been extremely confident in her ability to treat our son.
-
Dana is an amazing doctor that really has a handle on dealing not only with the patient but also with the families. She treats both sides with respect and I HIGHLY recommend her.
-
-
Award Name Award Description Awarded By Award Date SEATTLE'S TOP DOCTOR - 2019 Seattle Magazine 2019 SEATTLE'S TOP DOCTOR - 2018 Seattle Magazine 2018 SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017 Seattles Top Doctor 2016 Seattle Met Magazine 2016 SEATTLE MAGAZINE TOP DOCTOR - 2015 Seattle Magazine 2015 SEATTLE'S TOP DOCTOR - 2014 Seattle Metropolitan Magazine 2014 SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014 Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013 Seattle's Top Doc Seattle Met Magazine 2013 Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012 U.S. News Top Doctor U.S. News and World Report 2012 Scholar in Clinical Research Leukemia and Lymphoma Society 1999 - 2003 Trustee, then Medical Advisor Leukemia Society of America, Washington/Alaska Chapter 1995 - 2003 Trustee, then Medical Advisor Leukemia Society of America, Washington/Alaska Chapter 1995 - 2003 Special Fellow Leukemia Society of America 1992 Fellow, Leukemia Society of America 1987 Alpha Omega Alpha University of Washington, School of Medicine, Seattle, Washington 1981 Phi Beta Kappa University of Washington, Seattle, Washington 1977 -
Manuscripts in Refereed Journals
-
Click ES,Cox B, Olson SB, Grompe M, Akkari Y, Moreau LA, Shimamura A, Sternen DL, Liu YJ, Leppig KA, Matthews DC, Parisi MAFanconi anemia-like presentation in an infant with constitutional deletion of 21q including the RUNX1 gene
Am J Med Genet, 2011 : 155A(7)1673-9 -
Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb RF, Press OW, Appelbaum FRAllogeneic hematopoietic cell transplantation after conditioning with 131Ianti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Blood, 2010 : 1145444-5453 -
Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Applebaum FR, Press OWPretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia
Cancer Res, 2009 : 69185-192 -
Wise RP, Bonhoeffer J, Beeler J, Donato H, Downie P, Matthews D, Pool V, Riise-Bergsaker M, Tapiainen T, Verricchio FThe Brighton Collaboration Thrombocytopenia Working Group. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
Vaccine, 2007 : 255717-24 -
Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek E, Sickle E, Durack L, Carreras J, Horowitz MM, Press OW, Gopal AK, Martin PJ, Bernstein ID, Matthews DC131I-Anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
Blood, 2006 : 1072184-91 -
Mohit AA, David J. Fisher DJ, Matthews DC, Hoffer E, Avellino AMInferior Vena Cava thrombosis causing acute cauda equina syndrome: A case report.
J Neurosurgery, 2006 : 104(1 suppl)46-9 -
Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC.Biodistribution of yttrium-90 [90Y] labeled anti-CD45 antibody in a nonhuman primate model
Clinical Cancer Research, 2005 : 11787-794 -
Nester TA, Rumsey DM, Howell CC, Gilligan DM, Drachman JG, Maier RV, Kyles DM, Matthews DC, Pendergrass TWPrevention of sensitization to D+ RBCs using RBC exchange and IV Rh immune globulin.
Transfusion, 2004 : 441720-23 -
Beeson C, Butrynski JE, Hart JF, Nourigat CL, Matthews DC, Press OW, , Senter PD, Bernstein IDConditionally cleavable radioimmunoconjugates: A novel approach for the release of radioisotopes from radioimmunoconjugates
Bioconjug Chem, 2003 : 14927-33 -
Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OWA comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
Blood, 2003 : 1012340-2348 -
Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FA, Bernstein ID, Press OWHigh-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: a multivariable cohort analysis
Blood, 2003 : 1022351-7 -
Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, and Press OWHigh dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
Blood, 2002 : 993158-3162 -
Ruffner KL, Martin PJ, Hussell S, Nourigat C, Fisher DR, Bernstein ID, and Matthews DC.Immunosuppressive Effects of 131I-anti-CD45 Antibody in Unsensitized and Donor-Antigen Presensitized H2-Matched, Minor Antigen Mismatched Murine Transplant Models.
Cancer Research, 2001 : 615126-5131 -
Press OW, Eary JF, Gooley T, Gopal AJ, Liu S, Maloney DG, Petersdorf S, Martin PJ, Fisher D, Wood B, Porter B, Smith J, Matthews DC, Appelbaum FR, Bernstein ID.A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B cell lymphomas.
Blood, 2000 : 962934-2942 -
Wojtkowski TA, Rutledge JC, Matthews DCThe clinical impact of increased sensitivity PT and aPTT coagulation assays.
Amer. J. Clin. Pathol, 1999 : 112225-32 -
Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW.Follow-up of relapsed B-cell lymphoma patients treated with Iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
J Clin Oncol, 1998 : 163270-3278 -
Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey TR, Clift RA, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R.Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors
Blood, 1996 : 8751-58 -
Press OW, Shan D, Howell-Clark JH, Eary J, Appelbaum F, Matthews D, Hinman L, Shochat D, Bernstein ID.Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
Cancer Res, 1996 : 562123-2129 -
Walters MC, Patience M, Leisenring W, Eckman JR, Buchanan GR, Rogers ZR, Olivieri NE, Vichinsky E, Davies SC, Mentzer WC, Powars D, Scott JP, Bernaudin F, Ohene-Frempong K, Darbyshire PJ, Wayne A, Roberts IA, Dinndorf P, Brandalise S, Sanders JE, Matthews DC, Appelbaum FR, Storb, R, Sullivan KM.Barriers to bone marrow transplantation for sickle cell anemia.
Biology of Blood and Bone Marrow Transplant, 1996 : 2100-104 -
Anderson JE, Appelbaum FR, Schoch G, Gooley R, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey R, Clift RA, Deeg HJ, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Nash RA, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb K.Allogeneic marrow transplantation for myelodysplastic synodrome with advanced disease morphology: a Phase II study of busulfan, cyclophosphamide and total body irradiation and analysis of prognostic factors
J Clin Oncol, 1996 : 14200-6 -
Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernaudin F, Matthews DC, Storb R, Sullivan KMBone marrow transplantation for sickle cell disease: a multicenter collaborative investigation.
New Engl J Med, 1996 : 334369-76 -
Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf EW, Appelbaum FR, Buckner CD, Matthews D, Storb R, Sullivan KM, Hansen JAUnrelated donor marrow transplantation in children.
Blood, 1995 : 863247-3256 -
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW, Badger CC, Nelp WB, Bernstein IDDevelopment of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation
Blood, 1995 : 851122-1131 -
Walters MC, Sullivan KM, Bernaudin F, Souillet G, Vannier J-P, Johnson FL, Lenarsky C, Powars D, Bunin N, Ohene-Frempong K, Wall D, Michel G, Plouvier E, Bodigoni B, Lutz P, Sanders JE, Matthews DC, Patience M, Appelbaum FR, Storb RNeurologic complications following allogeneic marrow transplantation for sickle cell anemia.
Blood, 1995 : 85879-884 -
Eary JF, Pollard KR, Durack LD, Bice AN, Lewellen TK, Matthews D, Press OW, Nelp WB, Appelbaum FR, Bernstein IPost therapy imaging in high dose I-131 radioimmunotherapy patients
Med Phys, 1994 : 211157-1162 -
Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein IDRadiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support.
NEJM, 1993 : 3291219-1224 -
Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein IDUse of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
Transplantation, 1992 : 54829 - 833 -
van der Jagt RHC, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, Krohn KA, Bernstein IDTumor localization of radiolabeled anti-myeloid antibodies in a human acute leukemia xenograft model
Cancer Research, 1992 : 5289-94 -
Matthews DC, Appelbaum FR, Eary JF, Hui TE, Fisher D, Martin PJ, Durack L, Press OW, Nelp WB, Badger CD, Bernstein ID.Radiolabeled anti-CD45 monoclonal antibodies target hematolymphoid tissue in murine and macaque models
Antib. Immunoconjug. Radiopharm, 1991 : 4713-719 -
Badger CC, Davis J, Nourigat C, Wu ZM, Hui TE, Fisher DR, Shulman H, Appelbaum FR, Eary JF, Krohn K, Matthews DC, Bernstein IDBiodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
Cancer Research, 1991 : 515921-5928 -
Matthews DC, Appelbaum FR, Eary JF, Hui TE, Fisher DR, Martin PJ, Durack LD, Nelp WB, Press OW, Badger CC, Bernstein ID.Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
Blood, 1991 : 781864-1874
Published Abstracts
-
Ettinger RA, Puranik K, Epstein MS, Hughes RJ, Liberman JA, James EA, Howard TE, Cole SA, Matthews DC, Pratt, KPSequence-modified factor VIII variants having reduced immunogenicity
American Society of Hematology annual meeting, 2012 Dec. 8 - 2012 Feb. 11 -
Wong TE, Delaney M, Gernsheimer TB, Matthews DC, Brogan T, Mazor R, McMullan DM, Reiner AP, Konkle BA.Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: a retrospective cohort study.
American Society of Hematology Annual Meeting, 2012 Dec. 8 - 2012 Feb. 11 -
Ettinger RA, Liberman JA, Thompson AR, Matthews DC, Pratt, KPT cells from mild and severe hemophilia A inhibitor subjects recognized the same HLA-restricted epitope in factor VIII
National Hemophilia Foundation Annual Meeting, 2012 Nov. 8 - 2012 Jan. 10 -
Lewis KB, Nguyen P-C, Schuman JT, Howard TE, Walsh CE, Josephson NC, Matthews DC, Key NS, Pratt, KPDetermination of anti-factor VIIII antibody titers, isotypes and Epitopes by SPR Analysis of Human Plasma.
American Society of Hematology Annual Meeting, 2011 Dec. 9 - 2011 Feb. 13 -
Song K, White KK, Frost N, Eichinger J, Matthews DCInherited coagulopathic states as a risk factor for complications in pediatric spine patients.
International Meeting on Advanced Spine Techniques, 2008 July 8 - 2008 July 11
Other Publications
-
Matthews DCInherited disorders of platelet function
Pediatr Clin N Am, 2013 : 601475 -
Matthews DC and Glader BEErythrocyte disorders in infancy
Averys Diseases of the Newborn, 2012 : 91080-1107 -
McCrae K, Matthews D, Linenberger M.Consultative Hematology
American Society of Hematology Self-Assessment Program, 2007 : 3466-499 -
Ruffner KL and Matthews DCMonoclonal antibodies as anti-leukemia and anti-lymphoma drugs. In: Clinical Bone Marrow and Blood Stem Cell Transplantation
Clinical Bone Marrow and Blood Stem Cell Transplantation, 2004 : 3705-1715 -
Matthews DC and Appelbaum FR.Radioimmunotherapy and hematopoietic cell transplantation. In: Thomas Hematopoietic Cell Transplantation
Thomas Hematopoietic Cell Transplantation, 2004 : 3198-208 -
Nemecek ER and Matthews DCUse of radiolabeled antibodies in the treatment of childhood acute leukemia.
Pediatr Transplant, 2003 : 7(Suppl 3)89-94 -
Matthews DCRituximab in the very young: benefits in AIHA, at what risk? Invited "Inside Blood" capsule summary
Blood, 2003 : 1013761 -
Sievers EL, Matthews DC, Bernstein ID.Therapy of acute leukemia with monoclonal antibodies and immunoconjugates.
Treatment of Acute Leukemia: New Directions for Clinical Research, 2003 : 485-493 -
Nemecek ER and Matthews DCAntibody-based therapy of human leukemia
Curr Opin Hematol, 2002 : 9316-321 -
Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, and Press OWThe use of radioimmunoconjugates in stem cell transplantation.
Bone Marrow Transplantation, 2002 : 29807-816 -
Rosario E, Bernstein ID, Matthews DCMonoclonal antibodies in acute leukemia
New Frontiers in Cancer Therapy: Monoclonal antibody therapy of hematologic malignancies, 2001 : 219-236 -
Matthews DC, Sievers EL, Appelbaum FR, Eary J, Ruffner K, and Bernstein IDAntibody-Targeted Therapy Of AML: An Update. In: Autologous Marrow and Blood Transplantation: Proceedings of the Tenth International Symposium.
Autologous Marrow and Blood Transplantation: Proceedings of the Tenth International Symposium, 2001 : 229-242 -
Butrynski JE and Matthews DCNovel preparative regimens I: Tagged antibodies
Handbook of Bone Marrow Transplantation, 2000 : 65-94 -
Ruffner K and Matthews DCCurrent uses of monoclonal antibodies in the treatment of acute leukemia.
Semin Oncol, 2000 : 27Semin Oncol -
Ruffner K and Matthews DCRadioimmunotherapy in relapsed acute myeloid leukemia. Biologic Therapy of Leukemia:
Acute Leukemia, 2000 : 15-9 -
Matthews DCMonoclonal antibodies in the treatment of acute leukemia
193-197 Haematologica, 1999 : 84(Suppl 1) -
Matthews DCThe use of monoclonal antibodies in the treatment of AML
Hematology, 1999 : 1999138-142 -
Matthews DC.Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
Leukemia, 1998 : 12(Suppl 1)S22-S36 -
Matthews DC, Appelbaum FR, Press OW, Eary JF, Bernstein IDThe use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies
Winter JN: Blood Stem Cell Transplantation, 1997 : 121-139 -
Corcoran MC, Press OW, Matthews DC, Appelbaum FR, Bernstein IDThe role of radioimmunotherapy in bone marrow transplantation
Curr Opin Hematl, 1996 : 3438--45 -
Matthews DC, Appelbaum FR, Press OW, Eary JF, Bernstein IDTargeted therapy for hematologic malignancies: has its promise been realized?
Curr Opin Hematol, 1995 : 2235-239 -
Appelbaum FR, Press OW, Matthews D, Eary J, Martin PJ, Bernstein IDThe application of radioimmunotherapy to marrow transplantation.
Bone Marrow Transplantation, 1995 : 15(Supplement)S188-S192 -
Walters M, Matthews D, Sullivan DMBone marrow transplantation for hemoglobinopathy and sickle cell disease.
Recent Advances in Hematology, 1993 : 7119-134 -
Press OW, Appelbaum FR, Matthews DC, Eary JF, Badger CC, Martin PJ, Bernstein IDHigh dose radioimmunotherapy of lymphoma
Cancer Treatment and Research, 1993 : 6813-22 -
Appelbaum FR, Badger CC, Bernstein ID, Buckner CD, Deeg HJ, Eary JF, Matthews DC, Press OW, Storb R, Thomas EDIs there a better way to deliver total body irradiation?
Bone Marrow Transplantation, 1992 : 10(Suppl 1)77-81 -
Appelbaum FR, Matthews DC, Press OWTherapy of Hematologic Malignancies Using Radioimmunotherapy (RAIT)
Cambridge Medical Reviews: Haematology-Oncology, 1992 : 15-27 -
Matthews DC, Smith FO, Bernstein IDMonoclonal antibodies in the study and therapy of hematopoietic cancers.
Current Opinion in Immunology, 1992 : 4641-646 -
Bernstein ID, Press OW, Eary JF, Appelbaum FR, Badger CC, Matthews DC, Fisher DR, Martin PJ, Durack L, Levy R, Krohn K, Nelp WB, Thomas EDTreatment of leukemia and lymphoma using antibody labeled with high doses of 131I.
Antib. Immunoconjug. Radiopharm, 1991 : 4771-776 -
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Nelp WB, Krohn KA, Fisher D, Matthews D, Bernstein IDRadiolabeled antibody therapy of human B cell lymphomas: Advances in Experimental Biology and Medicine.
Immunobiology of Proteins and Peptides VI, 1991 : 91-96 -
Sullivan KM, Agura E, Anasetti C, Badger C, Bearman S, Erickson K, Flowers M, Loughran T, Martin P, Matthews D, Petersdorf E, Radich J, Riddell S, Rovira D, Sanders J, Schuening F, Siadak M, Witherspoon RP.Chronic graft-versus-host disease and the late complications of bone marrow transplantation.
Seminars in Hematology, 1991 : 28250-259 -
Sullivan KM, Witherspoon RP, Storb R, Anasetti C, Appelbaum F, Bigelow C, Clark J, Doney K, Hill R, Loughran T, Matthews DC, Nims J, Petersen F, Sanders J, Schuning F, Shields A, Strom S, Thomas EDChronic graft-versus-host disease: recent advances in diagnosis and treatment
Bone Marrow Transplantation: Current Controversies, 1989 : 91511-522, -
Sher BT, Bargatze R, Holzman B, Gallatin WM, Matthews D, Wu N, Picker L, Butcher E, and Weissman IL.Homing receptors and metastasis
Advances in Cancer Research, 1988 : 51361-390 -
Sullivan KM, Witherspoon R, Storb R, Appelbaum F, Beatty P, Bensinger W, Bigelow C, Buckner CD, Clift R, Doney K, Fefer A, Greenberg P, Hansen J, Martin P, Matthews D, McDonald G, Meyers J, Petersen FB, Sander J, Shulman H, Singer J, Stewart P, Thomas EDChronic graft-versus-host disease: pathogenesis, diagnosis, treatment and prognostic factors.
Recent Advances and Future Directions in Bone Marrow Transplantation. Experimental Hematology Today,Recent Advances and Future Directions in Bone Marrow Transplantation, 1987 : 150-157
-
-
Grant Title Grantor Amount Award Date Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia National Institutes of Health Sept. 30, 2010
Overview
- Board Certification(s)
-
Pediatric Hematology-Oncology
Pediatrics
- Medical/Professional School
-
University of Washington School of Medicine, Seattle
- Clinical Interests
-
Anemia, hemostasis, thrombosis, and autoimmune cytopenias
- Research Description
-
My research interests include risk-based optimization of the treatment of pediatric thrombosis, and clinical outcomes in patients with hemophilia. In particular, I am participating in projects including an effort to characterize immune responses to factor VIII that result in inhibiting antibodies that significantly complicate the management of hemophilia A, and a prospective study of the development of inhibitors in young patients with hemophilia.
Additionally, I am interested in improving the outcome for pediatric patients with thrombosis by developing clinical trials for subgroups of patients with thrombosis.
- Research Focus Area
-
Blood Disorders
